Generic pharmaceutical company Hindustan Laboratories has filed its draft papers for an initial public offering (IPO) with the market regulator to raise funds for business expansion and working capital requirements.
The proposed Hindustan Laboratories IPO will consist of a fresh issue of 50 lakh equity shares, along with an offer for sale (OFS) of 91 lakh shares by Rajesh Vasantray Doshi, the companyтАЩs sole promoter. Proceeds from the fresh issue will be used primarily to fund working capital needs, while funds raised through the OFS will go to the promoter.
Hindustan Laboratories operates in the generic drugs segment, catering to domestic and export markets with a portfolio of affordable pharmaceutical products. The IPO is expected to support the companyтАЩs operational scale and improve financial flexibility as it navigates competitive pressures in the pharma sector.
The filing adds to the growing pipeline of healthcare and pharmaceutical IPOs, reflecting continued investor interest in companies focused on cost-effective medicines and long-term healthcare demand.
